The risks and challenges of the global COVID-19-vaccine rollout
The world has seen great wave of resilience and heroic effort in facing the pandemic challenge. After the high stressing time when world experienced the historical lock down period, downscaling business and ordinary life activities, halted the human life globally. After the heroic quest of scientists to develop a coronavirus vaccine, its global rollout has started globally.
The vaccines of the BioNTech and Pfizer partnership (Pfizer–BioNTech) and Moderna have received Emergency Use Authorization in number of countries. Many frontline workers and priority population segments have already received their first doses. Vaccines from other global players like AstraZeneca, Johnson & Johnson, and several other manufacturers are also arriving (or are expected to arrive soon) and are being distributed for administration around the world.
This heroic effort has shaken the previous research based vaccine development record.
To go back to post-pandemic era, Brobdingnagian numbers of dedicated field experts will have to continue working intensely in the months and years ahead.
Which also means that we would need vast batches of trained experts to fulfil the gap, in research…
